The U.S. regulator has cleared Ultragenyx Pharmaceutical’s gene therapy for glycogen storage disease type Ia.
Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration has approved its gene therapy for the treatment of glycogen storage disease type Ia (GSDIa).
Further details regarding launch timing, pricing, or commercial availability were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
